Predict progression free survival and overall survival using objective response rate for anti—PD1/PDL1 therapy development-Reference-Cited by-同舟云学术

Predict progression free survival and overall survival using objective response rate for anti—PD1/PDL1 therapy development

Published:2024-07-29 Issue:1 Volume:24 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Yang Lei,Raveendran Geethanjali,Meng Xiang,Lin Ji,Meng Zhaoling

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12885-024-12664-1.pdf

Reference26 articles.

1. Tiantian H, Yuan G, Ruyang Z, Yongyue W, Feng C. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. BMC Cancer. 2022;22(1):1–13.

2. Runcong N, Foping C, Shuqiang Y, Yingshan L, Shi C, Yongming C, Xiaojiang C, Yingbo C, Yuanfang Li, Zhiwei Z. Evaluation of objective response, disease control and progression-free survival as surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. Eur J Cancer. 2019;106:1–11.

3. Jiabu Ye, Xiang Ji, Dennis Phillip A, Hesham A, Pralay M. Relationship between progression-free survival, objective response rate, and overall survival in clinical trials of PD-1/PD-L1 immune checkpoint blockade: a meta-analysis. Clin Pharmacol Ther. 2020;108(6):1274–88.

4. Clarke JM, Wang X, Ready NE. Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials – are we in a new era? Translational Lung Cancer Research. 2015;4:804–8.

5. Zhu Andrew X, Lin Yong, Ferry David Raymond, Widau Ryan C, Saha Abhijoy. Meta-analysis of surrogate endpoints for survival in patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based regimens. Am Soc Clin Oncol. 2022;40(4):Abstract 483.